Spyre Therapeutics, Inc.
SYRE· Nasdaq
SYRESpyre Therapeutics, Inc.
Filed Feb 19, 2026 · 10-K · 50 days after period end · 0001636282-26-000020
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $168.00K |
| Net Income | -$62.53M | -$56.30M | -$63.18M | -$18.82M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Feb 19, 2026 · 50 d after period end
